OBJECTIVE: To determine the incremental cost-effectiveness of a quality improvement depression intervention (enhanced care) in primary care settings relative to usual care. DESIGN: Following stratification, we randomized 12 primary care practices to enhanced or usual care conditions and followed patients for 12 months. SETTING: Primary care practices located in 10 states across the United States. PATIENTS/PARTICIPANTS: Two hundred eleven patients beginning a new treatment episode for major depression. INTERVENTIONS: Training the primary care team to assess, educate, and monitor depressed patients during the acute and continuation stages of their depression treatment episode over 1 year. MEASUREMENTS AND MAIN RESULTS: Cost-effectiveness was measured by calculating incremental (enhanced minus usual care) costs and quality-adjusted life years (QALYs) derived from SF-36 data. The mean incremental cost-effectiveness ratio in the main analysis was US dollars 15463 per QALY. The mean incremental cost-effectiveness ratios for the sensitivity analyses ranged from US dollars 11341 (using geographic block variables to control for pre-intervention service utilization) to US dollars 19976 (increasing the cost estimates by 50%) per QALY. CONCLUSIONS: This quality improvement depression intervention was cost-effective relative to usual care compared to cost-effectiveness ratios for common primary care interventions and commonly cited cost-effectiveness ratio thresholds for intervention implementation.
OBJECTIVE: To determine the incremental cost-effectiveness of a quality improvement depression intervention (enhanced care) in primary care settings relative to usual care. DESIGN: Following stratification, we randomized 12 primary care practices to enhanced or usual care conditions and followed patients for 12 months. SETTING: Primary care practices located in 10 states across the United States. PATIENTS/PARTICIPANTS: Two hundred eleven patients beginning a new treatment episode for major depression. INTERVENTIONS: Training the primary care team to assess, educate, and monitor depressed patients during the acute and continuation stages of their depression treatment episode over 1 year. MEASUREMENTS AND MAIN RESULTS: Cost-effectiveness was measured by calculating incremental (enhanced minus usual care) costs and quality-adjusted life years (QALYs) derived from SF-36 data. The mean incremental cost-effectiveness ratio in the main analysis was US dollars 15463 per QALY. The mean incremental cost-effectiveness ratios for the sensitivity analyses ranged from US dollars 11341 (using geographic block variables to control for pre-intervention service utilization) to US dollars 19976 (increasing the cost estimates by 50%) per QALY. CONCLUSIONS: This quality improvement depression intervention was cost-effective relative to usual care compared to cost-effectiveness ratios for common primary care interventions and commonly cited cost-effectiveness ratio thresholds for intervention implementation.
Authors: K B Wells; C Sherbourne; M Schoenbaum; N Duan; L Meredith; J Unützer; J Miranda; M F Carney; L V Rubenstein Journal: JAMA Date: 2000-01-12 Impact factor: 56.272
Authors: D J Katzelnick; G E Simon; S D Pearson; W G Manning; C P Helstad; H J Henk; S M Cole; E H Lin; L H Taylor; K A Kobak Journal: Arch Fam Med Date: 2000-04
Authors: E M Hunkeler; J F Meresman; W A Hargreaves; B Fireman; W H Berman; A J Kirsch; J Groebe; S W Hurt; P Braden; M Getzell; P A Feigenbaum; T Peng; M Salzer Journal: Arch Fam Med Date: 2000-08
Authors: Me Domino; J Maxwell; M Cody; K Cheal; A Busch; Ww Van Stone; Sg Cooley; C Zubtritsky; Cl Estes; Y Shen; M Lynch; S Grantham; P Wohlford; Mc Aoyama; J Fitzpatrick; S Zaman; J Dodson; Se Levkoff Journal: Ageing Int Date: 2008-06-01
Authors: Dennis W Raisch; Heather M Campbell; David A Garnand; Mark A Jones; Mike R Sather; Rupali Naik; Walter Ling Journal: Qual Life Res Date: 2011-10-11 Impact factor: 4.147
Authors: Jacob T Painter; John C Fortney; Allen L Gifford; David Rimland; Thomas Monson; Maria C Rodriguez-Barradas; Jeffrey M Pyne Journal: J Acquir Immune Defic Syndr Date: 2015-12-01 Impact factor: 3.731
Authors: Katherine E Watkins; Alison E Cuellar; Kimberly A Hepner; Sarah B Hunter; Susan M Paddock; Brett A Ewing; Erin de la Cruz Journal: J Subst Abuse Treat Date: 2013-10-02
Authors: Jeanne Miranda; Michael K Ong; Loretta Jones; Bowen Chung; Elizabeth L Dixon; Lingqi Tang; Jim Gilmore; Cathy Sherbourne; Victoria K Ngo; Susan Stockdale; Esmeralda Ramos; Thomas R Belin; Kenneth B Wells Journal: J Gen Intern Med Date: 2013-05-14 Impact factor: 5.128